Syndrome News and Research

RSS

56 percent of pregnant women in UK hospitals with COVID-19 are BAME

According to a new national surveillance study released this week, over half of the pregnant women admitted to a hospital in the United Kingdom with COVID-19 are either black or belong to other ethnic minority groups.

8 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

Researchers confirm new therapeutic target for myelodysplastic syndrome

A research group from Kumamoto University, Japan analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of the transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered a tumor suppressor.

8 Jun 2020

SARS-CoV-2 infection causes specific kidney proximal tubular injury

SARS-CoV-2-associated acute kidney injury (AKI) is one of the more frequently encountered organ involvements in COVID-19 - in as many as 80% of critically ill patients, according to a recent study.

8 Jun 2020

Improving detection of SARS-CoV-2 infection among severely ill children

Researchers in the UK have conducted a study showing that children with a severe inflammatory syndrome had high levels of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite having tested negative for the virus by polymerase chain reaction (PCR).

8 Jun 2020

Irradiation with UV light kills SARS-CoV-2

Researchers in Italy have found that it is possible to completely inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using short-wavelength UV (UV-C) irradiation.

8 Jun 2020

Monocytes could be critical in dysregulated immunity in COVID-19

A new study by Spanish researchers as part of the GEN-COVID Project, and published on the preprint server medRxiv* in June 2020, suggests that monocytes are primarily involved in triggering the hyperinflammatory immune response that may underlie severe COVID-19 infection.

8 Jun 2020

The receptor binding domain of the SARS-CoV-2

With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.

8 Jun 2020

Inhibition of coronavirus spike protein binding to ACE2

A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.

8 Jun 2020

SARS-CoV-2 invasion of central nervous system through olfactory tract

As the COVID-19 pandemic continues to claim lives throughout the world, the evidence is mounting that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract as well as the central nervous system. Now, a new study by German researchers published on the preprint server bioRxiv in June 2020 describes various neurological manifestations of COVID-19, as well as the underlying pathophysiology.

7 Jun 2020

Tocilizumab in COVID-19 patients on mechanical ventilation

Now, a new study by researchers from the University of Michigan and published on the online preprint server medRxiv* in June 2020 shows that the cytokine inhibitor tocilizumab could have a favorable effect on survival in the most severely infected patients who require mechanical ventilation. This needs to be confirmed by clinical trials.

7 Jun 2020

New strategy may facilitate development of multi-epitope peptide vaccine against SARS-CoV-2

By combining T and B lymphocyte analysis with manufacturability heuristic, researchers from the US and Germany proposed a set of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine peptides to use in subsequent animal studies and clinical trials. Their paper is currently available on the bioRxiv preprint server.

7 Jun 2020

Kidney enzyme renalase a potential therapy for severe COVID-19

Researchers from Yale School of Medicine have discovered that a low blood level of an enzyme called renalase is associated with severe coronavirus disease 2019 (COVID-19).

7 Jun 2020

Zinc-finger antiviral protein makes SARS-CoV-2 highly susceptible to interferons

By looking into zinc-finger antiviral proteins (ZAP), a new study from Germany and the United Kingdom (UK) and available on the preprint server bioRxiv suggests that zoonotic transmission of a coronavirus with a specific genetic make-up facilitated the pandemic spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also its sensitivity to interferons.

7 Jun 2020

Approved drug could help dampen massive immune response associated with severe COVID-19

The drug acalabrutinib, FDA-approved for the treatment of several types of B cell cancers, improved the oxygenation levels and decreased molecular markers of inflammation in a majority of 19 patients hospitalized for the treatment of severe COVID-19, according to a new study by Mark Roschewski and colleagues.

5 Jun 2020

Study: MafB protein may protect against renal failure

Focal segmental glomerulosclerosis (FSGS) is a common cause of steroid-resistant nephrotic syndrome, a type of kidney disease that is accompanied by massive urinary protein loss and that may progress to end-stage renal disease.

5 Jun 2020

Antiviral effects for COVID-19: Early is better

A new study by an international team of researchers and published on the preprint server medRxiv* in June 2020 describes the possible reasons for inconsistent or null findings in clinical studies of antiviral drugs to date. It proposes a new approach to decide the sample size in light of its findings.

5 Jun 2020

Precautions for intimacy, sex, during COVID-19

Amid the coronavirus disease (COVID-19) pandemic, safe sex practices are as important as other measures to prevent infection. Little focus has been given to sexual health, but a new study highlights how couples can reduce the transmission of the novel coronavirus.

5 Jun 2020

WHO resumes hydroxychloroquine drug trial in COVID-19

The coronavirus disease (COVID-19) has rippled across the world with a devastating effect. As scientists raced to find an effective treatment for patients, existing malaria and rheumatoid arthritis drug hydroxychloroquine became one of the most popular candidates.

5 Jun 2020

U.K. doctors test lipid ibuprofen as COVID-19 treatment

The non-steroidal anti-inflammatory drug (NSAID) Ibuprofen is being tested as a potential treatment for the coronavirus disease (COVID-19). Doctors in the United Kingdom rolled out a clinical trial of the everyday painkiller to see if it reduces respiratory failure in patients experiencing severe COVID-19 disease.

4 Jun 2020